Skip to content
10-Q

Quarterly Report

AOXING PHARMACEUTICAL COMPANY, INC.

0001096906-16-002058

← back to feed
Filed
Nov 14, 2016 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2017 · Nov 14, 2016 76.21M sh
Capex Q1 2017 · Sep 30, 2016 $2.13K
Capex Q1 2017 · Sep 30, 2015 $81.5K
Operating Cash Flow Q1 2017 · Sep 30, 2016 $134.94K
Operating Cash Flow Q1 2017 · Sep 30, 2015 $390.15K
Short Term Debt Q1 2017 · Sep 30, 2016 $8.54M
Short Term Debt Q1 2017 · Jun 30, 2016 $11.07M
Stockholders Equity Q1 2017 · Sep 30, 2016 $19.53M
Stockholders Equity Q1 2017 · Jun 30, 2016 $19.14M
Current Liabilities Q1 2017 · Sep 30, 2016 $39.84M
Current Liabilities Q1 2017 · Jun 30, 2016 $37.82M
Current Assets Q1 2017 · Sep 30, 2016 $30.1M
Current Assets Q1 2017 · Jun 30, 2016 $26.87M
Total Assets Q1 2017 · Sep 30, 2016 $58.77M
Total Assets Q1 2017 · Jun 30, 2016 $56.23M
Sga Expense Q1 2017 · Sep 30, 2016 $1.28M
Sga Expense Q1 2017 · Sep 30, 2015 $944.36K
Rd Expense Q1 2017 · Sep 30, 2016 $377.29K
Rd Expense Q1 2017 · Sep 30, 2015 $377.31K
Net Income Q1 2017 · Sep 30, 2016 $391.76K
Net Income Q1 2017 · Sep 30, 2015 $1.35M
Operating Income Q1 2017 · Sep 30, 2016 $1.7M
Operating Income Q1 2017 · Sep 30, 2015 $3.14M
Gross Profit Q1 2017 · Sep 30, 2016 $6.05M
Gross Profit Q1 2017 · Sep 30, 2015 $6.99M
Cost Of Revenue Q1 2017 · Sep 30, 2016 $1.51M
Cost Of Revenue Q1 2017 · Sep 30, 2015 $1.76M